NHS Puberty Blockers Trial Gets Green Light

The trial, which had been paused after a 2024 ban on routine prescribing of puberty blockers for gender dysphoria, was challenged by campaigners who argued it would cause irreversible harm to children.

The judge ruled that the trial could proceed, allowing recruitment to begin immediately.

The case has reignited the debate over transgender healthcare for minors, with the UK government supporting the trial as part of evidence-based care.

Critics, including some medical professionals, say the drugs are experimental and that psychological support should be the first line of treatment.